Viking Therapeutics is projected to report $0.00 in revenue and a consensus EPS loss of $1.06 for Q3 2026, with shares trading at approximately $24.40 against an average analyst price target of $96.15.
Investors are primarily monitoring the clinical progress of VK2735, focusing specifically on the recently initiated Phase 3 SUNRISE trials for the drug's oral formulation.
Recent volatility has seen the stock decline 41% due to rising R&D burn and a $500 million capital raise. Management's updates on trial enrollment and weight-loss maintenance durability will be critical for competing with market leaders Eli Lilly and Novo Nordisk.